EMMA — Emmaus Life Sciences Share Price
0.000.00%
Last trade - 00:00- $1.05m
- $29.55m
- $16.65m
- 19
- 90
- 19
- 38
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | n/a | ||
| Price to Tang. Book | n/a | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 0.06 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | n/a | ||
| Return on Equity | n/a | ||
| Operating Margin | -5.18% | ||
Financial Summary
| Year End 31st Dec | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 23.17 | 20.61 | 18.39 | 29.6 | 16.65 | 22.8 | n/a | -6.05% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Emmaus Life Sciences, Inc. is a commercial-stage biopharmaceutical company. The Company is engaged in the discovery, development, marketing and sale of treatments and therapies, primarily for rare and orphan diseases. Its lead product, Endari (prescription grade L-glutamine oral powder) helps to reduce the acute complications of sickle cell disease (SCD) in adult and pediatric patients five years of age and older. Its product pipeline includes ELS001/ELS007, ELS004, ELS005, ELS003, and ELS002. The Company, through Kainos Medicine, Inc. (Kainos), has a license in the territory encompassing the United States, the United Kingdom, and the European Union to patent rights, know-how, and other intellectual property relating to Kainos’s IRAK4 inhibitor, referred to as KM10544, for the treatment of cancers, including leukemia, lymphoma, and solid tumor cancers. The Company has also developed chondrocyte and osteoblast cell sheets using human mesenchymal stem cells.
Directors
- Yutaka Niihara CHM (61)
- Yasushi Nagasaki CFO (54)
- Willis Lee COO (61)
- Robert Dickey IND (65)
- Masaharu Osato IND (66)
- Lori Teranishi IND
- Jane Wood IND (58)
- Wei Peu Zen IND (68)
- Ian Zwicker IND (73)
- Last Annual
- December 31st, 2024
- Last Interim
- December 31st, 2024
- Incorporated
- March 20th, 1987
- Public Since
- May 9th, 2000
- No. of Shareholders
- 395
- No. of Employees
- 34
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- Pink Sheets on Nasdaq
- Shares in Issue
- 63,865,571
- Address
- 21250 HAWTHORNE BOULEVARD, SUITE 800, TORRANCE, 90503
- Web
- https://www.emmausmedical.com/
- Phone
- +1 3102140065
- Auditors
- Marcum LLP
Upcoming Events for EMMA
Q1 2025 Emmaus Life Sciences Inc Earnings Release
Similar to EMMA
Actavia Life Sciences
Pink Sheets on Nasdaq
Acura Pharmaceuticals
Pink Sheets on Nasdaq
Adhera Therapeutics
Pink Sheets on Nasdaq
Ramoil Management
Pink Sheets on Nasdaq
Adynxx
Pink Sheets on Nasdaq
FAQ
What is the Emmaus Life Sciences share price?
As of Today at 20:26 UTC, shares in Emmaus Life Sciences are trading at $0.02. This share price information is delayed by 15 minutes.
How has the Emmaus Life Sciences share price performed this year?
Shares in Emmaus Life Sciences last closed at $0.02 and the price had moved by -83.5% over the past 365 days. In terms of relative price strength the Emmaus Life Sciences share price has underperformed the S&P500 Index by -84.7% over the past year.
What are the analyst and broker recommendations for Emmaus Life Sciences?
The overall consensus recommendation for Emmaus Life Sciences is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreWhat is the Emmaus Life Sciences dividend yield?
Emmaus Life Sciences does not currently pay a dividend.
Does Emmaus Life Sciences pay a dividend?
Emmaus Life Sciences does not currently pay a dividend.
When does Emmaus Life Sciences next pay dividends?
Emmaus Life Sciences does not currently pay a dividend.
How do I buy Emmaus Life Sciences shares?
To buy shares in Emmaus Life Sciences you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Emmaus Life Sciences?
As of the previous close price of $0.02, shares in Emmaus Life Sciences had a market capitalisation of $1.05m.
Where are Emmaus Life Sciences shares listed?
Here are the trading details for Emmaus Life Sciences:
- Country of listing: United States
- Exchange: PNK
- Ticker Symbol: EMMA
What kind of share is Emmaus Life Sciences?
Based on an overall assessment of its quality, value and momentum Emmaus Life Sciences is currently classified as a Value Trap. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Emmaus Life Sciences share price forecast for 2025?
The analyst consensus target price for shares in Emmaus Life Sciences is $4.00. That is 24142.42% above the last closing price of $0.02.
Analysts covering Emmaus Life Sciences currently have a consensus Earnings Per Share (EPS) forecast of -$0.06 for the next financial year.
Find out moreWhat is the trend in the Emmaus Life Sciences share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Emmaus Life Sciences. Over the past six months, its share price has underperformed the S&P500 Index by -58.64%.
As of the last closing price of $0.02, shares in Emmaus Life Sciences were trading -70.61% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Emmaus Life Sciences PE Ratio?
The Emmaus Life Sciences PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $0.02.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Emmaus Life Sciences?
Emmaus Life Sciences' management team is headed by:
- Yutaka Niihara - CHM
- Yasushi Nagasaki - CFO
- Willis Lee - COO
- Robert Dickey - IND
- Masaharu Osato - IND
- Lori Teranishi - IND
- Jane Wood - IND
- Wei Peu Zen - IND
- Ian Zwicker - IND